


FIG. 1



*Dosing Cohort 2 begins enrolling after the first ~5 participants in Dosing Cohort 1 have completed Week 5 and the DMC has reviewed the relevant and available participant data and approves the initiation of Dosing Cohort 2.

FIG. 2A




FIG. 2B





FIG. 3






FIG. 4D






FIG. 4E



- Plasma C3 (PD)
- Plasma PK

FIG. 5
5 mg/kg Compound C
(days after dosing)








FIG. 6E




FIG. 6D




FIG. 8






FIG. 9




** $P < 0.004$ vs. 3, 10, or 30 mg/kg Compound B

FIG. 11A



* $P < 0.01$ (group AUC vs. AUC of anti-Fx1A)
** $P < 0.005$ (group AUC vs. AUC of anti-Fx1A)
*** $P < 0.0001$ (group AUC vs. AUC of anti-Fx1A)

FIG. 11B




* $P < 0.01$ (group AUC vs. AUC of anti-Fx1A)

** $P < 0.005$ (group AUC vs. AUC of anti-Fx1A)


*** $P < 0.0001$ (group AUC vs. AUC of anti-Fx1A)

FIG. 11C




* $P < 0.01$ (group AUC vs. AUC of anti-Fx1A)
** $P < 0.005$ (group AUC vs. AUC of anti-Fx1A)
*** $P < 0.0001$ (group AUC vs. AUC of anti-Fx1A)

FIG. 12A



* $P < 0.05$, *** $P < 0.0001$ vs. PBS
* $P < 0.05$, ** $P < 0.005$ vs. equiv. dose Fc-fH₁₋₅

FIG. 12B



*** $P < 0.001$, **** $P < 0.0001$

FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14




FIG. 15




FIG. 16




FIG. 17A




FIG. 17B

	COMPOUND B Treated										Part 2 - MAD Summary	
	Part 1 - SAD Summary								Summary		Summary	
	Cohort 1 (N = 4)	Cohort 2 (N = 4)	Cohort 3 (N = 4)	Cohort 4a (N = 4)	Cohort 4b (N = 4)	Cohort 6a (N = 4)	Cohort 6b (N = 4)	Cohort 8 (N = 4)	COMP.B (N = 32)	Placebo (N = 17)	COMP.B (N = 4)	Placebo (N = 3)
Age (years) ^a												
Mean (SD)	31.8 (13.8)	32.0 (12.9)	27.3 (9.9)	37.3 (14.2)	35.8 (18.2)	28.5 (7.6)	36.0 (9.7)	36.0 (11.0)	33.1 (11.6)	33.2 (11.0)	44.0 (14.5)	32.3 (19.6)
Min, max	21, 52	23, 51	18, 41	27, 58	18, 56	21, 38	28, 50	24, 48	18, 58	18, 59	29, 60	21, 55
Sex, n (%)												
Male	1 (25.0)	0	0	1 (25.0)	1 (25.0)	3 (75.0)	0	2 (50.0)	8 (25.0)	7 (41.2)	2 (50.0)	0
Female	3 (75.0)	4 (100)	4 (100)	3 (75.0)	3 (75.0)	1 (25.0)	4 (100)	2 (50.0)	24 (75.0)	10 (58.8)	2 (50.0)	3 (100)
Race, n (%)												
Asian	0	0	0	1 (25.0)	1 (25.0)	0	0	0	2 (6.3)	1 (5.9)		
White	4 (100)	4 (100)	4 (100)	3 (75.0)	3 (75.0)	4 (100)	4 (100)	4 (100)	30 (93.8)	16 (94.1)	4 (100)	3 (100)
Weight (kg) ^b												
Mean (SD)	75.80 (25.09)	60.30 (10.10)	59.88 (7.39)	65.38 (10.58)	78.28 (13.61)	67.43 (18.55)	68.48 (8.85)	74.65 (20.15)	68.56 (15.03)	72.20 (15.53)	78.10 (7.35)	67.20 (7.55)
Min, max	57.2, 112.1	50.9, 73.1	51.1, 69.0	55.2, 79.8	61.5, 90.6	46.1, 90.0	59.0, 77.9	52.7, 92.4	46.1, 112.0	51.0, 99.7	67.3, 83.2	59.5, 74.6
BMI (kg/m ²) ^c												
Mean (SD)	26.23 (5.91)	22.60 (4.77)	21.53 (1.88)	24.25 (2.78)	25.58 (4.19)	23.13 (4.18)	24.33 (5.22)	24.65 (4.28)	23.95 (3.95)	23.29 (3.26)	24.33 (2.16)	22.83 (2.27)
Min, max	19.8, 32.1	17.4, 26.9	18.8, 23.0	20.3, 26.7	21.5, 31.3	18.0, 28.1	19.7, 31.2	18.7, 28.8	17.8, 32.0	18.8, 28.9	21.7, 26.3	21.1, 25.4

FIG. 17C

Number of Participants with a TEAE Provided by Preferred Term	Part 1 - SAD								Part 2 - MAD		
	Cohort 1 (N = 6) n (%)	Cohort 2 (N = 6) n (%)	Cohort 3 (N = 6) n (%)	Cohort 4a (N = 6) n (%)	Cohort 4b (N = 6) n (%)	Cohort 6a (N = 6) n (%)	Cohort 6b (N = 6) n (%)	Cohort 8 (N = 6) n (%)	Total (N = 49) n (%)	Cohort 1 (N = 7) n (%)	Total (N = 7) n (%)
Total number of participants with any TEAE	4 (66.7)	3 (50.0)	4 (66.7)	4 (66.7)	2 (33.3)	7 (100.0)	4 (66.7)	5 (83.3)	33 (67.3)	7 (100.0)	7 (100.0)
Headache	0	2 (33.3)	4 (66.7)	2 (33.3)	1 (16.7)	3 (42.9)	1 (16.7)	0	13 (26.5)	1 (14.3)	1 (14.3)
Nasopharyngitis	0	0	0	3 (50.0)	1 (16.7)	1 (14.3)	2 (33.3)	1 (16.7)	8 (16.3)	4 (57.1)	4 (57.1)
Injection site reaction	0	0	0	0	2 (33.3)	0	3 (50.0)	0	5 (10.2)	4 (57.1)	4 (57.1)
Blood creatine phosphokinase increased	1 (16.7)	0	0	0	0	1 (14.3)	0	0	2 (4.1)	0	0
Cough	0	0	0	0	0	2 (28.6)	0	0	2 (4.1)	2 (28.6)	2 (28.6)
COVID-19	0	0	0	0	1 (16.7)	0	0	2 (33.3)	3 (6.1)	1 (14.3)	1 (14.3)
Hot flush	0	0	0	0	0	0	0	2 (33.3)	2 (4.1)	0	0
Back pain	0	0	0	1 (16.7)	0	0	0	0	1 (2.0)	1 (14.3)	1 (14.3)
Panic attack	0	0	0	1 (16.7)	0	1 (14.3)	0	0	2 (4.1)	0	0
Dysmenorrhoea	0	1 (16.7)	0	0	0	0	0	1 (16.7)	2 (4.1)	0	0
Rhinitis	0	0	0	0	0	1 (14.3)	0	0	1 (2.0)	1 (14.3)	1 (14.3)

FIG. 17D




FIG. 17E




FIG. 17F




FIG. 17G




FIG. 17H




FIG. 17I




FIG. 17J




FIG. 17K

